MedPath

Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)

Phase 3
Withdrawn
Conditions
Substance Abuse
Depression
Anxiety
Externalizing Symptoms
Interventions
Behavioral: CATCH-IT
Behavioral: AMPE
Registration Number
NCT01228890
Lead Sponsor
University of Chicago
Brief Summary

In this 5-year, two-site randomized clinical trial, we propose to test the efficacy of the CATCH-IT primary care/Internet based depression prevention intervention against Attention Monitoring Psychoeducation (AMPE) in preventing the onset of depressive episodes in an intermediate to high risk group of adolescents aged 13-17. We plan to (a) identify high risk adolescents based on elevated scores on the PHQ-A, a screening measure of depressive symptoms; (b) recruit 400 (200 per site) of these at-risk adolescents to be randomized into either the CATCH-IT or the AMPE group; (c) assess outcomes at 2, 8, 12, 18, and 24 months post intake on measures of depressive symptoms, depressive diagnoses, other mental disorders, and on measures of role impairment in education, quality of life, attainment of educational milestones, and family functioning; and (d) conduct exploratory analyses to examine the effectiveness of this intervention program, moderators of protection, and potential ethnic and cultural differences in intervention response.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Youth ages 13 through 17.
  • Youth must be experiencing elevated level of depressive symptoms on the Center for Epidemiologic Studies Depression46 (CES-D) scale (score >/= 16) and have at least two core symptoms of Major Depression on the Patient Health Questionnaire, Adolescents.
  • Youth will be included if they have a past history of depression, anxiety, externalizing symptoms, or substance abuse.
Read More
Exclusion Criteria
  • Current DSM-IV diagnosis (Kiddie Schedule of Affective Disorders) of Major Depressive Disorder, current therapy for depression, or be taking antidepressants (e.g., SSRIs, TCAs, MAOIs, bupropion, nefazodone, mirtazapine, venlafaxine).
  • Current CES-D score >35
  • DSM-IV diagnosis of schizophrenia (current or past) or bipolar affective disorder
  • Current serious medical illness that causes significant disability or dysfunction
  • Significant reading impairment (a minimum sixth-grade reading level based on parental report), mental retardation, or developmental disabilities
  • Serious imminent suicidal risk (as determined by endorsement of current suicidality on CES-D or in KSADS interview) or other conditions that may require immediate psychiatric hospitalization
  • Psychotic features or disorders, or currently be receiving psychotropic medication
  • Extreme, current drug/alcohol abuse (greater than or equal to 2 on the CRAFFT).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CATCH-IT 2-R ArmCATCH-ITPrimary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
Attention Monitoring Psycho-education (AMPE) ArmAMPE-
Primary Outcome Measures
NameTimeMethod
To determine whether the CATCH-IT 2-R depression prevention intervention prevents or delays major depressive episodes, as well as non-affective disorder episodes, compared to AMPE.49-60 months from beginning of trial
Secondary Outcome Measures
NameTimeMethod
To determine if participants in the CATCH-IT 2-R group exhibit more rapid favorable changes of depressive symptoms/and or vulnerability/protective factors compared with the AMPE group.49-60 months from beginning of the trial
To determine if participants in the CATCH-IT 2-R program report lower perceived educational impairment, greater quality of life, greater health-related quality of life, and lower incidence of other mental disorders (anxiety, substance/alcohol use).49-60 months from beginning of trial
To determine for whom (moderators) and how (mediators) the CATCH-IT 2-R program works in this population.49-60 months from beginning of trial

Trial Locations

Locations (4)

University of Chicago

🇺🇸

Chicago, Illinois, United States

Access Community Health Network

🇺🇸

Chicago, Illinois, United States

Northshore University Health Systems

🇺🇸

Evanston, Illinois, United States

Harvard Vanguard Medical Associates

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath